Trial Profile
A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SENIOR
- Sponsors Sanofi
- 12 Jun 2018 Primary endpoint has been met. (Change in HbA1c From Baseline to Week 26) as per results published in the Diabetes Care
- 12 Jun 2018 Results published in the Diabetes Care
- 08 Dec 2017 Results of a secondary analysis, presented at the 2017 Congress of the International Diabetes Federation.